Literature DB >> 21676920

Cognitive dysfunction in SLE: development of a screening tool.

T Adhikari1, A Piatti, M Luggen.   

Abstract

BACKGROUND: Cognitive dysfunction (CD) is among the most common neuropsychiatric manifestations of systemic lupus erythematosus (SLE). There are two methods which have been used to detect CD in patients with SLE: traditional neuropsychological tests (NPT) and the Automated Neuropsychological Assessment Metrics (ANAM). Both are time-consuming and neither is readily available for screening purposes.
PURPOSE: The aim of our study was to evaluate the Montreal Cognitive Assessment (MoCA) test as a screening tool for detection of CD in SLE. Methods. SLE patients fulfilling ACR criteria were administered the ANAM, a computerized test battery which measures various cognitive domains and the MoCA, a one-page, performance-based screening test designed to detect mild cognitive impairment in the elderly. With the ANAM as the gold standard, the performance characteristics of the MoCA were assessed.
RESULTS: In total, 44 patients were evaluated. Of these, 11 (25%) were identified by the ANAM as being impaired in comparison with 13 (29.5%) by the MoCA. The scores were significantly correlated (r = 0.57, p < 0.001). Using the standard cutoff of 26, the sensitivity of MoCA was 83% and specificity 73%.
CONCLUSION: The MoCA appears to be a promising screening tool for the detection of CD in SLE both for epidemiologic studies and for routine clinical care.

Entities:  

Mesh:

Year:  2011        PMID: 21676920     DOI: 10.1177/0961203311405374

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  9 in total

Review 1.  Biomarkers for CNS involvement in pediatric lupus.

Authors:  Tamar B Rubinstein; Chaim Putterman; Beatrice Goilav
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

2.  Absence of association between nailfold capillary findings and mild cognitive dysfunction in systemic lupus erythematosus.

Authors:  Pamela Munguía-Realpozo; Mario García-Carrasco; Claudia Mendoza-Pinto; María de Lourdes Galaviz-Silva; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Álvaro José Montiel-Jarquín; Luis G Vázquez de Lara; Luis H Silveira
Journal:  Clin Rheumatol       Date:  2022-05-27       Impact factor: 3.650

Review 3.  Optimizing pharmacotherapy of systemic lupus erythematosus: the pharmacist role.

Authors:  Maryam Al Hussaini; Emad I Hammouda; Ahmed E Hammouda
Journal:  Int J Clin Pharm       Date:  2014-07-02

Review 4.  Cognitive Dysfunction in Systemic Lupus Erythematosus: Immunopathology, Clinical Manifestations, Neuroimaging and Management.

Authors:  Dominic Seet; Nur Azizah Allameen; Jiacai Cho; Anselm Mak; Sen Hee Tay
Journal:  Rheumatol Ther       Date:  2021-05-15

Review 5.  Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus.

Authors:  Sen Hee Tay; Anselm Mak
Journal:  Int J Mol Sci       Date:  2015-05-06       Impact factor: 5.923

6.  Brain metabolism and autoantibody titres predict functional impairment in systemic lupus erythematosus.

Authors:  Meggan Mackay; Chris C Tang; Bruce T Volpe; Cynthia Aranow; Paul J Mattis; Ricki A Korff; Betty Diamond; David Eidelberg
Journal:  Lupus Sci Med       Date:  2015-03-28

7.  The Montreal Cognitive Assessment Test: A Useful Tool in Screening of Cognitive Impairment in Patients With Systemic Lupus Erythematosus.

Authors:  Nicolas Paez-Venegas; Bethel Jordan-Estrada; Efrain Chavarria-Avila; Felipe Perez-Vazquez; Eduardo Gómez-Bañuelos; Rafael Medina-Dávalos; José-Ángel Ontiveros-González; Gustavo-Ignacio Diaz-Rubio; Rosa E Navarro-Hernandez; Mónica Vázquez-Del Mercado
Journal:  J Clin Rheumatol       Date:  2019-12       Impact factor: 3.517

8.  Evaluation of the Montreal Cognitive Assessment as a screening tool for cognitive dysfunction in SLE.

Authors:  Sudha Raghunath; Yifat Glikmann-Johnston; Eric Morand; Julie C Stout; Alberta Hoi
Journal:  Lupus Sci Med       Date:  2021-12

Review 9.  Cognitive dysfunction in autoimmune rheumatic diseases.

Authors:  Csaba Oláh; Noa Schwartz; Christopher Denton; Zsófia Kardos; Chaim Putterman; Zoltán Szekanecz
Journal:  Arthritis Res Ther       Date:  2020-04-15       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.